3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Neoplasms
1
Melanoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Camurati-Engelmann Syndrome
1
Breast Neoplasms
1
Interventions
pembrolizumab
92
Nivolumab
56
Ipilimumab
55
Cyclophosphamide
52
Vemurafenib
28
fludarabine
27
aldesleukin
25
Interleukin-2
25
fludarabine phosphate
21
trametinib
20
dabrafenib
17
Temozolomide
14
Biopsy
14
Cisplatin
13
spartalizumab
12
atezolizumab
12
Carboplatin
11
cobimetinib
10
Paclitaxel
10
Introns
10
CTLA-4 Antigen
10
poly ICLC
9
binimetinib
9
Specimen Handling
9
Radiotherapy
9
Radiosurgery
9
MART-1 Antigen
9
tremelimumab
8
incomplete Freund's adjuvant
8
Radiation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Melanoma
×
LY3300054
×
Clear all
NCT02791334
2024-09-27
PACT
Eli Lilly and Company
Phase 1
Completed
164 enrolled